Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Disc Medicine, Inc. Director's Dealing 2021

Apr 7, 2021

31589_dirs_2021-04-07_e1915bfc-6b62-4530-943e-9313040d2c26.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Gemini Therapeutics, Inc. /DE (GMTX)
CIK: 0001816736
Period of Report: 2021-03-12

Reporting Person: Lubner David Charles (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-02-05 Stock Option (Right to Buy) $12.66 A 58855 Acquired 2031-02-04 Common Stock (58855) Direct

Footnotes

F1: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 5, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a Service Relationship with the Company.